Immunohistochemistry (IHC) : Human lung adenocarcinoma stained with anti-PD-L1 (Clone ZR3) using peroxidase-conjugate and DAB chromogen. Note membranous staining of tumor cells.

rabbit anti-PD-L1 monoclonal antibody (ZR3) 6328

$160.00 – $528.00

Antibody summary

Rabbit monoclonal to PD-L1
Suitable for: Immunohistochemistry (formalin-fixed, paraffin-embedded tissues)
Reacts with: Human
Isotype:IgG
Control: Placenta or lung adenocarcinoma
Visualization: Membrane
0.1, 0.5, 1.0 mL concentrated, 7 mL prediluted

available sizes

Clear

SKU: 6328parent Category: antibody Tags: anatomy, General & Epithelial Markers, monoclonal, PD-L1

Weight	1 lbs
Dimensions	9 × 5 × 2 in
host	mouse
isotype	IgG
clonality	monoclonal
concentration	concentrate, predilute
applications	IHC
reactivity	human
available size	0.1 mL, 0.5 mL, 1 mL concentrated, 7 mL prediluted

rabbit anti-PD-L1 monoclonal antibody ZR3 6328

antibody
Database link: human Q9NZQ7
Tested applications IHC
Recommended dilutions Concentrated 1:100-200
Application Notes Positive control: Placenta or lung adenocarcinoma
Immunogen KLH-conjugated linear peptide corresponding tohuman PD-L1
Size and concentration 7 mL prediluted or 0.1, 0.5, 1.0 mL and concentrated
Form liquid
Storage Instructions 2-8°C for short term, for longer term at -20°C. Avoid freeze / thaw cycles.
Purity affinity purified
Clonality monoclonal
Isotype IgG
Compatible secondaries goat anti-rabbit IgG, H&L chain specific, peroxidase conjugated, conjugated polyclonal antibody 9512 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody 2079 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody 7863 goat anti-rabbit IgG, H&L chain specific, Cross Absorbed polyclonal antibody 2371 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1715 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1720
Isotype control Rabbit polyclonal - Isotype Control

target relevance
Protein names Programmed cell death 1 ligand 1 (PD-L1) (PDCD1 ligand 1) (Programmed death ligand 1) (hPD-L1) (B7 homolog 1) (B7-H1) (CD antigen CD274)
Gene names CD274,CD274 B7H1 PDCD1L1 PDCD1LG1 PDL1
Protein family Immunoglobulin superfamily, BTN/MOG family
Mass 33275Da
Function FUNCTION: Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed:32929201). {ECO:0000269\|PubMed:10581077, ECO:0000269\|PubMed:11015443, ECO:0000269\|PubMed:28813410, ECO:0000269\|PubMed:28813417, ECO:0000269\|PubMed:31399419, ECO:0000269\|PubMed:32929201, ECO:0000269\|PubMed:36727298}.; FUNCTION: The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813410, PubMed:28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity). {ECO:0000250\|UniProtKB:Q9EP73, ECO:0000269\|PubMed:28813410, ECO:0000269\|PubMed:28813417}.
Subellular location SUBCELLULAR LOCATION: Cell membrane {ECO:0000269\|PubMed:28813410, ECO:0000269\|PubMed:28813417, ECO:0000269\|PubMed:36232715}; Single-pass type I membrane protein {ECO:0000255}. Early endosome membrane {ECO:0000269\|PubMed:28813417}; Single-pass type I membrane protein {ECO:0000255}. Recycling endosome membrane {ECO:0000269\|PubMed:28813417}; Single-pass type I membrane protein {ECO:0000255}. Nucleus {ECO:0000269\|PubMed:32929201}. Note=Associates with CMTM6 at recycling endosomes, where it is protected from being targeted for lysosomal degradation (PubMed:28813417). Translocates to the nucleus in response to hypoxia via its interaction with phosphorylated STAT3 (PubMed:32929201). {ECO:0000269\|PubMed:28813417, ECO:0000269\|PubMed:32929201}.; SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane {ECO:0000269\|PubMed:15780196}; Single-pass type I membrane protein {ECO:0000255}.; SUBCELLULAR LOCATION: [Isoform 2]: Endomembrane system {ECO:0000269\|PubMed:15780196}; Single-pass type I membrane protein {ECO:0000255}.; SUBCELLULAR LOCATION: [Isoform 4]: Secreted {ECO:0000269\|PubMed:30564891}.
Tissues TISSUE SPECIFICITY: Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes. {ECO:0000269\|PubMed:10581077, ECO:0000269\|PubMed:11015443}.; TISSUE SPECIFICITY: [Isoform 4]: Widely expressed, highest in lung, liver and pituitary and in various peripheral blood cells, including neutrophils and some subtypes of lymphoid and myeloid cells. {ECO:0000269\|PubMed:30564891}.
Structure SUBUNIT: Interacts with PDCD1 (PubMed:11015443, PubMed:18287011, PubMed:26602187). Interacts (via transmembrane domain) with CMTM4 and CMTM6 (PubMed:28813410, PubMed:28813417). Interacts with (phosphorylated) STAT3; promoting nuclear translocation (PubMed:32929201). Interacts with CD80 (PubMed:36727298). {ECO:0000269\|PubMed:11015443, ECO:0000269\|PubMed:18287011, ECO:0000269\|PubMed:26602187, ECO:0000269\|PubMed:28813410, ECO:0000269\|PubMed:28813417, ECO:0000269\|PubMed:32929201, ECO:0000269\|PubMed:36727298}.; SUBUNIT: [Isoform 4]: May form homomultimers. {ECO:0000269\|PubMed:30564891}.
Post-translational modification PTM: Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation (PubMed:28813410). Ubiquitinated by MARCHF8; leading to degradation (PubMed:34183449). Deubiquitinated by USP22; leading to stabilization (PubMed:31399419). {ECO:0000269\|PubMed:28813410, ECO:0000269\|PubMed:31399419, ECO:0000269\|PubMed:34183449}.
Involvement in disease DISEASE: Note=Truncation of the 3'-untranslated (3'-UTR) region of CD274 transcripts leads to elevated expression of CD274 in multiple cancers including T-cell leukemia, diffuse large B-cell lymphoma and stomach adenocarcinoma (PubMed:27281199). Disruption of 3'-UTR region is caused by structural variants that stabilize CD274 transcripts, leading to overexpression (PubMed:27281199). Increased expression in tumors promotes immune evasion and tumor cell growth by allowing malignant cells to escape destruction by the immune system (PubMed:27281199). {ECO:0000269\|PubMed:27281199}.
Target Relevance information above includes information from UniProt accession: Q9NZQ7
The UniProt Consortium

Data

Human lung adenocarcinoma stained with anti-PD-L1 (Clone ZR3) using peroxidase-conjugate and DAB chromogen. Note membranous staining of tumor cells.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.